Venture&Growth
Location
Barcelona, Spain 
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
Splice Bio is a biotech company based on intein technologies developed in the Muir Lab at Princeton University. They are working with their proprietary platform to address key limitations of current gene therapy approaches to treat patients in need. The company is building a product pipeline of gene therapies targeting inherited retinal diseases and other severe genetic diseases for which there is no cure.
More Splice Bio news
Gilde Healthcare company SpliceBio enters $216 million Gene Therapy collaboration with Spark Therapeutics
Gilde Healthcare invests in Eur 50M series A round of Spanish Gene Therapy company SpliceBio
CatalYm
CatalYm is a clinical-stage immuno-oncology company improving the outcomes of existing checkpoint inhibitor therapies in...
Lava Therapeutics
Dutch Therapeutics company developing antibody-based therapy to treat cancer.
Acacia Pharma
Belgian Therapeutics company commercializing supportive care products to treat side effects of medical procedures.
